Bothell's Nastech Pharmaceutical Co. said Tuesday that it would lay off employees and overhaul its operations -- a week after losing its second major drug partner in two years. On Nov. 6, ...

Last week, Nastech Pharmaceutical (NASDAQ:NSTK) reported a net loss of $11.5 million on revenues of $5 million, ending the first quarter with just over $81 million in cash and investments. Recent ...

BOTHELL — Nastech Pharmaceutical Co. lost its heavyweight partner for development of a spray to treat osteoporosis, but it now plans to pursue the potential product on its own. The company said ...

Nastech Pharmaceutical’s independent auditors expressed concern about the biotech company’s ability to survive due to a possible cash crunch, according to a regulatory filing Monday. Accounting firm ...

Consumer-products giant Procter & Gamble pulled out of a potentially lucrative partnership with Bothell-based Nastech Pharmaceuticals because its nasal spray for treating osteoporosis wasn’t working ...

BOTHELL, Wash. -- Jun 9, 2008 - Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today data from a Phase II clinical trial demonstrating that its ultra rapid acting intranasal insulin was ...

Whitehouse Station’s Merck (NYSE: MRK) and Nastech Pharmaceutical (NasdaqNM: NSTK) of Bothell, Washington, Monday announced a global alliance to develop and commercialize Peptide YY 3-36 nasal spray ...

BOTHELL, Wash., Sept. 26 Nastech PharmaceuticalCompany Inc. (Nasdaq: NSTK) announced today the start of a Phase 2 clinicaltrial evaluating the Company's rapid-acting Insulin Nasal Spray ...

BOTHELL — Nastech Pharmaceutical Co. has a new name, stock symbol and chief executive officer today to match a seismic shift in the biotechnology firm’s focus. In recent months, the ­Bothell-based ...

Shares in US group Nastech fell as much as 36% in trading yesterday, as investor confidence was hammered on the news that US drug giant Merck & Co has returned the rights to PYY3-36, the firm’s ...

Shares of Nastech Pharmaceutical Co. Inc. jumped 18 percent Wednesday on news of a potential $577 million deal with Procter & Gamble Pharmaceuticals Inc. to develop Nastech's nasal spray for ...

"Nastech has developed a strong clinical pipeline of innovative therapeutics using our proprietary drug delivery technologies which are aimed at providing patients with a safe and effective method of ...